Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Retapamulin

FDA-approved product (ointment, topical), marketed as Altabax.

Registered studies
19
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Retapamulin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Impetigo
  • Staphylococcal skin infections

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibiotics for topical use
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D06AX13

Repurposing investigation

Retapamulin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

19registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Retapamulin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Retapamulin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Retapamulin as a Decolonizing Agent for MRSA

    NCT03304873 · start 2017-12-01

    Registered record
    Registry ID
    NCT03304873
    Conditions
    MRSA
    Interventions
    Retapamulin; Placebo Ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-01
    Completion
    2019-03-18
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMRSA
    InterventionRetapamulin; Placebo Ointment
    PhasePhase 3
    Registry statusCompleted

  • Retapamulin Microdialysis Feasibility Study

    NCT01812382 · start 2014-04-02

    Registered record
    Registry ID
    NCT01812382
    Conditions
    Skin Infections, Bacterial
    Interventions
    Retapamulin Microdialysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04-02
    Completion
    2014-05-27
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Infections, Bacterial
    InterventionRetapamulin Microdialysis
    PhasePhase 1
    Registry statusCompleted

  • ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)

    NCT01445600 · start 2012-11

    Registered record
    Registry ID
    NCT01445600
    Conditions
    Skin Infections, Bacterial
    Interventions
    ALTARGO(retapamulin)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-11
    Completion
    2015-08
    Enrolment
    3,612

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Infections, Bacterial
    InterventionALTARGO(retapamulin)
    PhaseNot recorded
    Registry statusCompleted

  • Retapamulin for Reducing MRSA Nasal Carriage

    NCT01461668 · start 2012-07

    Registered record
    Registry ID
    NCT01461668
    Conditions
    Methicillin-Resistant Staphylococcus Aureus
    Interventions
    Retapamulin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-07
    Completion
    2017-12
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-Resistant Staphylococcus Aureus
    InterventionRetapamulin; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

    NCT01397461 · start 2012-03

    Registered record
    Registry ID
    NCT01397461
    Conditions
    Impetigo
    Interventions
    ozenoxacin placebo; retapamulin 1% ointment; ozenoxacin 1% cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2012-12
    Enrolment
    465

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImpetigo
    Interventionozenoxacin placebo; retapamulin 1% ointment; ozenoxacin 1% cream
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Staphylococcus Aureus Colonization in Hand Eczema

    NCT01591785 · start 2012-01

    Registered record
    Registry ID
    NCT01591785
    Conditions
    Hand Eczema; Foot Eczema
    Interventions
    Retapamulin 1% ointment; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-01
    Completion
    2012-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand Eczema; Foot Eczema
    InterventionRetapamulin 1% ointment; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

    NCT01126268 · start 2010-04

    Registered record
    Registry ID
    NCT01126268
    Conditions
    Impetigo; Folliculitis; Secondarily Infected Eczema; Minor Soft Tissue Infections
    Interventions
    Retapamulin (Altabax)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-04
    Completion
    2012-11
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImpetigo; Folliculitis; Secondarily Infected Eczema; Minor Soft Tissue Infections
    InterventionRetapamulin (Altabax)
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis

    NCT01064947 · start 2010-02

    Registered record
    Registry ID
    NCT01064947
    Conditions
    Atopic Dermatitis; Secondary Infection
    Interventions
    Retapamulin 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-02
    Completion
    2012-01
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis; Secondary Infection
    InterventionRetapamulin 1%
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery

    NCT00903279 · start 2009-08

    Registered record
    Registry ID
    NCT00903279
    Conditions
    Orthopedic Procedures; Methicillin-resistant Staphylococcus Aureus
    Interventions
    Placebo; Altabax (retapamulin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2009-08
    Completion
    2010-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOrthopedic Procedures; Methicillin-resistant Staphylococcus Aureus
    InterventionPlacebo; Altabax (retapamulin)
    PhasePhase 2
    Registry statusWithdrawn

  • Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization

    NCT00856089 · start 2009-05

    Registered record
    Registry ID
    NCT00856089
    Conditions
    Methicillin-resistant Staphylococcus Aureus
    Interventions
    Retapamulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2009-05
    Completion
    2009-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-resistant Staphylococcus Aureus
    InterventionRetapamulin
    PhasePhase 4
    Registry statusWithdrawn

  • Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

    NCT00871208 · start 2009-05

    Registered record
    Registry ID
    NCT00871208
    Conditions
    Atopic Dermatitis
    Interventions
    Altabax (R); Vehicle and Locoid lipocream (R)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2009-05
    Completion
    2010-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionAltabax (R); Vehicle and Locoid lipocream (R)
    PhasePhase 4
    Registry statusWithdrawn

  • Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

    NCT00852540 · start 2009-04

    Registered record
    Registry ID
    NCT00852540
    Conditions
    Skin Infections, Bacterial
    Interventions
    Retpamulin Ointment, 1%; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-09
    Enrolment
    410

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Infections, Bacterial
    InterventionRetpamulin Ointment, 1%; Linezolid
    PhasePhase 3
    Registry statusCompleted

  • United States Pharmacovigilence Retapamulin-Prescribing

    NCT01153880 · start 2008-12

    Registered record
    Registry ID
    NCT01153880
    Conditions
    Skin Infections, Bacterial
    Interventions
    Retapamulin; Co-prescription of retapamulin and topical mupirocin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-12
    Completion
    2012-08
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Infections, Bacterial
    InterventionRetapamulin; Co-prescription of retapamulin and topical mupirocin
    PhaseNot recorded
    Registry statusCompleted

  • EU PV for Retapamulin-Prescribing

    NCT01153828 · start 2008-11

    Registered record
    Registry ID
    NCT01153828
    Conditions
    Impetigo
    Interventions
    Retapamulin; Co-prescription of retapamulin and topical mupirocin; Co-prescription of retapamulin and topical fusidic acid
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-11
    Completion
    2012-08
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImpetigo
    InterventionRetapamulin; Co-prescription of retapamulin and topical mupirocin; Co-prescription of retapamulin and topical fusidic acid
    PhaseNot recorded
    Registry statusCompleted

  • Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

    NCT00684177 · start 2008-05

    Registered record
    Registry ID
    NCT00684177
    Conditions
    Skin Infections, Bacterial
    Interventions
    Retapamulin Ointment, 1%; Placebo ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-05
    Completion
    2009-10
    Enrolment
    508

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Infections, Bacterial
    InterventionRetapamulin Ointment, 1%; Placebo ointment
    PhasePhase 3
    Registry statusCompleted